Gevorgyan A - Search Results

1

Chronomodulated capecitabine and adjuvant radiation in intermediate-risk to high-risk rectal cancer: a phase II study.

Bajetta E, Pietrantonio F, Buzzoni R, Ferrario E, Valvo F, Mariani L, Dotti KF, Biondani P, Formisano B, Gevorgyan A, Grassi P, Di Bartolomeo M. Bajetta E, et al. Among authors: gevorgyan a. Am J Clin Oncol. 2014 Dec;37(6):545-9. doi: 10.1097/COC.0b013e31827ecd1d. Am J Clin Oncol. 2014. PMID: 23428953 Clinical Trial.

2

Irinotecan, fluorouracil and folinic acid (FOLFIRI) as effective treatment combination for patients with advanced gastric cancer in poor clinical condition.

Beretta E, Di Bartolomeo M, Buzzoni R, Ferrario E, Mariani L, Gevorgyan A, Bajetta E. Beretta E, et al. Among authors: gevorgyan a. Tumori. 2006 Sep-Oct;92(5):379-83. doi: 10.1177/030089160609200502. Tumori. 2006. PMID: 17168428 Clinical Trial.

3

Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma. A randomized phase III trial.

Di Bartolomeo M, Buzzoni R, Mariani L, Ferrario E, Katia D, Gevorgyan A, Zilembo N, Bordonaro R, Bochicchio AM, Massidda B, Ardizzoia A, Marini G, Aitini E, Schieppati G, Comella G, Pinotti G, Palazzo S, Cicero G, Bajetta E; Italian Trial in Medical Oncology (ITMO) Group; Villa E, Fagnani D, Reguzzoni G, Agostana B, Oliani C, Kildani B, Duro M, Botta M, Mozzana R, Mantovani G. Di Bartolomeo M, et al. Among authors: gevorgyan a. Oncology. 2006;71(5-6):341-6. doi: 10.1159/000108575. Epub 2007 Sep 14. Oncology. 2006. PMID: 17855795 Clinical Trial.

4

Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients.

Bajetta E, Di Bartolomeo M, Buzzoni R, Ferrario E, Dotti KF, Mariani L, Bajetta R, Gevorgyan A, Venturino P, Galassi M. Bajetta E, et al. Among authors: gevorgyan a. Cancer Chemother Pharmacol. 2009 Jun;64(1):67-72. doi: 10.1007/s00280-008-0852-1. Epub 2008 Oct 21. Cancer Chemother Pharmacol. 2009. PMID: 18936940 Clinical Trial.

5

Feasibility study of biweekly capecitabine, oxaliplatin, and irinotecan in patients with untreated advanced gastric cancer.

Bajetta E, Verzoni E, Ferrario E, Dotti K, Gevorgyan A, Celio L. Bajetta E, et al. Among authors: gevorgyan a. Tumori. 2009 Jan-Feb;95(1):43-7. doi: 10.1177/030089160909500108. Tumori. 2009. PMID: 19366055 Clinical Trial.

6

Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation.

Pietrantonio F, Perrone F, de Braud F, Castano A, Maggi C, Bossi I, Gevorgyan A, Biondani P, Pacifici M, Busico A, Gariboldi M, Festinese F, Tamborini E, Di Bartolomeo M. Pietrantonio F, et al. Among authors: gevorgyan a. Ann Oncol. 2014 Feb;25(2):404-8. doi: 10.1093/annonc/mdt547. Epub 2013 Dec 29. Ann Oncol. 2014. PMID: 24379162 Free article. Clinical Trial.

7

Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma.

Procopio G, Verzoni E, Gevorgyan A, Mancin M, Pusceddu S, Catena L, Platania M, Guadalupi V, Martinetti A, Bajetta E. Procopio G, et al. Among authors: gevorgyan a. Oncology. 2007;73(3-4):204-9. doi: 10.1159/000127387. Epub 2008 Apr 16. Oncology. 2007. PMID: 18418013

8

Role of the antiangiogenic agent bevacizumab in the treatment of elderly patients with metastatic colorectal cancer.

Di Bartolomeo M, Pietrantonio F, Martinetti A, Buzzoni R, Gevorgyan A, Bajetta E. Di Bartolomeo M, et al. Among authors: gevorgyan a. Drugs Aging. 2011 Feb 1;28(2):83-91. doi: 10.2165/11584710-000000000-00000. Drugs Aging. 2011. PMID: 21155618 Review.

9

Circulating biomarkers in advanced colorectal cancer patients randomly assigned to three bevacizumab-based regimens.

Martinetti A, Miceli R, Sottotetti E, Di Bartolomeo M, de Braud F, Gevorgyan A, Dotti KF, Bajetta E, Campiglio M, Bianchi F, Bregni G, Pietrantonio F. Martinetti A, et al. Among authors: gevorgyan a. Cancers (Basel). 2014 Aug 29;6(3):1753-68. doi: 10.3390/cancers6031753. Cancers (Basel). 2014. PMID: 25256831 Free PMC article.

10

Clinical update on palonosetron in the management of chemotherapy-induced nausea and vomiting.

Celio L, Denaro A, Canova S, Gevorgyan A, Bajetta E. Celio L, et al. Among authors: gevorgyan a. Tumori. 2008 Jul-Aug;94(4):447-52. doi: 10.1177/030089160809400401. Tumori. 2008. PMID: 18822676 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

100 results

Search Page

Filters